WO2003102160A3 - Rationally designed polysaccharide lyases derived from chondroitinase b - Google Patents

Rationally designed polysaccharide lyases derived from chondroitinase b Download PDF

Info

Publication number
WO2003102160A3
WO2003102160A3 PCT/US2003/017680 US0317680W WO03102160A3 WO 2003102160 A3 WO2003102160 A3 WO 2003102160A3 US 0317680 W US0317680 W US 0317680W WO 03102160 A3 WO03102160 A3 WO 03102160A3
Authority
WO
WIPO (PCT)
Prior art keywords
chondroitinase
rationally designed
polysaccharide lyases
inhibiting
relates
Prior art date
Application number
PCT/US2003/017680
Other languages
French (fr)
Other versions
WO2003102160A2 (en
Inventor
Kevin Pojasek
Rahul Raman
Ram Sasisekharan
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Priority to CA002493509A priority Critical patent/CA2493509C/en
Priority to EP03756399A priority patent/EP1532241B1/en
Priority to AT03756399T priority patent/ATE481478T1/en
Priority to DE60334220T priority patent/DE60334220D1/en
Priority to AU2003243396A priority patent/AU2003243396A1/en
Publication of WO2003102160A2 publication Critical patent/WO2003102160A2/en
Publication of WO2003102160A3 publication Critical patent/WO2003102160A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention relates to rationally designed polysaccharide lyases and uses thereof. In particular, the invention relates to modified chondroitinase B. The modified chondroitinase B enzymes of the invention are useful for a variety of purposes, including cleaving and sequencing polysaccharides such as glycosaminoglycans (GAGs) as well as removing polysaccharides from a solution. The invention also includes methods of inhibiting anticoagulant activity, inhibiting angiogenesis, treating cancer, and inhibiting maternal malarial infection.
PCT/US2003/017680 2002-06-03 2003-06-03 Rationally designed polysaccharide lyases derived from chondroitinase b WO2003102160A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002493509A CA2493509C (en) 2002-06-03 2003-06-03 Rationally designed polysaccharide lyases derived from chondroitinase b
EP03756399A EP1532241B1 (en) 2002-06-03 2003-06-03 Rationally designed polysaccharide lyases derived from chondroitinase b
AT03756399T ATE481478T1 (en) 2002-06-03 2003-06-03 RATIONALLY DESIGNED LYASES DERIVED FROM CHONDROITINASE B
DE60334220T DE60334220D1 (en) 2002-06-03 2003-06-03 Rationally Constructed Lyases Derived from Chondroitinase B.
AU2003243396A AU2003243396A1 (en) 2002-06-03 2003-06-03 Rationally designed polysaccharide lyases derived from chondroitinase b

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38550902P 2002-06-03 2002-06-03
US60/385,509 2002-06-03

Publications (2)

Publication Number Publication Date
WO2003102160A2 WO2003102160A2 (en) 2003-12-11
WO2003102160A3 true WO2003102160A3 (en) 2004-09-16

Family

ID=29712183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017680 WO2003102160A2 (en) 2002-06-03 2003-06-03 Rationally designed polysaccharide lyases derived from chondroitinase b

Country Status (7)

Country Link
US (4) US6962699B2 (en)
EP (1) EP1532241B1 (en)
AT (1) ATE481478T1 (en)
AU (1) AU2003243396A1 (en)
CA (1) CA2493509C (en)
DE (1) DE60334220D1 (en)
WO (1) WO2003102160A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687479B2 (en) 2000-09-12 2010-03-30 Massachusetts Institute Of Technology Methods and producing low molecular weight heparin
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7842492B2 (en) 2007-01-05 2010-11-30 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US7939292B2 (en) 2000-03-08 2011-05-10 Massachusetts Institute Of Technology Modified heparinase III and methods of sequencing therewith
US8018231B2 (en) 2002-05-20 2011-09-13 Massachussetts Institute Of Technology Method for sequence determination using NMR
US8529889B2 (en) 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527822A (en) * 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー Rationally designed heparinases from heparinases I and II
JP2002531217A (en) * 1998-12-04 2002-09-24 チャンドラシェカー ピー． パサック， Biocompatible crosslinked polymer
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
EP1575534B1 (en) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase and uses thereof
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
EP1532241B1 (en) * 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
WO2004017044A2 (en) * 2002-08-15 2004-02-26 Acorda Therapeutics, Inc. Chimeric protein
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2016204464B2 (en) * 2003-05-16 2018-03-22 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
EP1631237B1 (en) * 2003-05-16 2016-11-30 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US20080025963A1 (en) * 2003-05-16 2008-01-31 Gruskin Elliott A Compositions and methods for the treatment of CNS injuries
US20070161599A1 (en) * 2003-05-28 2007-07-12 The Board Of Trustees Of The University Of Illinois Composition for blocking hiv binding to dendritic cells and methods of use thereof
US7507570B2 (en) * 2004-03-10 2009-03-24 Massachusetts Institute Of Technology Recombinant chondroitinase ABC I and uses thereof
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
CA2566731C (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
EP2008096A2 (en) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glycomic patterns for the detection of disease
WO2008045970A2 (en) 2006-10-10 2008-04-17 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
GB0712302D0 (en) * 2007-06-22 2007-08-01 Cambridge Entpr Ltd Chrondroitinase polypeptides
US20090286289A1 (en) * 2008-03-10 2009-11-19 Pang Danny Z Production of Hyaluronate Unsaturated Disaccharides and its Application
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9796970B1 (en) 2017-04-24 2017-10-24 Advantek Serum Laboratories Ltd. Production of high purity chondroitinase ABC
CN111593040B (en) * 2020-06-20 2022-08-30 山东大学 Dermatan sulfate lyase and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093563A (en) * 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US91472A (en) * 1869-06-15 Improvement in plows
US91471A (en) * 1869-06-15 steigmeyer
US197933A (en) * 1877-12-11 Improvement in wood-screws
US99628A (en) * 1870-02-08 Signors to themselves and a
US169143A (en) * 1875-10-26 Improvement in perforating stamps
US92037A (en) * 1869-06-29 Improved shoe-pegging- machine
US204869A (en) * 1878-06-11 Improvement in weighing-scales
US122793A (en) * 1872-01-16 Improvement in air-supplying attachments for stoves
US191587A (en) * 1877-06-05 Improvement in piano-forte bridges
US128225A (en) * 1872-06-25 Improvement in workmen s time-registers
US37376A (en) * 1863-01-06 Improvement in breech-loading fire-arms
US8820A (en) * 1852-03-23 Improvement in friction-primers for cannon
JPS6031478B2 (en) 1978-02-10 1985-07-22 生化学工業株式会社 Method for producing pure chondroitinase B
US4341869A (en) * 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US5169772A (en) * 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
JP2726275B2 (en) 1988-08-24 1998-03-11 生化学工業株式会社 Purification of glycosaminoglycan degrading enzyme
JPH0693836B2 (en) * 1988-11-25 1994-11-24 新技術事業団 Heparinase-producing microorganism belonging to the genus Bacillus, novel heparinase, and method for producing the same
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
JPH04270327A (en) * 1991-02-26 1992-09-25 Fuji Photo Optical Co Ltd Exposure correcting device for camera
JP3110064B2 (en) * 1991-03-06 2000-11-20 生化学工業株式会社 Novel heparitinase, method for producing the same and bacteria producing the same
US5262325A (en) * 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
US5668274A (en) 1991-04-23 1997-09-16 Akzo Nobel N.V. Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type
US5714376A (en) * 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
US5773277A (en) * 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
US6001630A (en) * 1992-06-26 1999-12-14 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896
US5496718A (en) * 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
JP3419811B2 (en) 1993-02-24 2003-06-23 マルハ株式会社 Chondroitinase gene
US5389539A (en) * 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
CN1115182A (en) 1993-09-30 1996-01-17 生化学工业株式会社 Antithrombotic
WO1995013830A1 (en) 1993-11-17 1995-05-26 Massachusetts Institute Of Technology Method for inhibiting angiogenesis using heparinase
US5525500A (en) 1994-04-22 1996-06-11 American Cyanamid Company Chromatographic process for the copurification of chondroitinase I and II proteins from Proteus vulgaris
EP0756636A4 (en) 1994-04-22 1997-12-17 American Cyanamid Co Chondroitinases i and ii, methods of preparation, and use thereof
US5498536A (en) 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
US5681733A (en) * 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) * 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US5965507A (en) * 1995-06-08 1999-10-12 Procter & Gamble Company Cleaning compositions comprising chondroitinase
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
IT1285546B1 (en) 1996-01-16 1998-06-18 Alfa Wassermann Spa USE OF LOW MOLECULAR WEIGHT DERMATANE SULFATE AND MEDICINAL SPECIALTIES THAT CONTAIN IT IN THE THERAPY AND PREVENTION OF
EP0875253B1 (en) 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase compositions
DE69808402T2 (en) * 1997-08-22 2003-07-03 Seikagaku Kogyo Co Ltd Medicines to treat intervertebral disc disorder caused by hernia
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US6378527B1 (en) * 1998-04-08 2002-04-30 Chondros, Inc. Cell-culture and polymer constructs
AU3985499A (en) 1998-05-13 1999-11-29 Biomarin Pharmaceutical Inc. Lytic enzymes useful for treating fungal infections
JP2000044601A (en) 1998-07-29 2000-02-15 Seikagaku Kogyo Co Ltd New galactosaminoglucan
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
AU1608701A (en) 1999-11-12 2001-06-06 Biomarin Pharmaceutical Inc. Lytic enzymes useful for treating fungal infections
ATE413886T1 (en) 1999-11-17 2008-11-15 Biomarin Pharm Inc REDUCING ANGIOGENESIS USING CHONDROITIN SULPHATE DEGRADING ENZYMES
WO2001038399A1 (en) 1999-11-24 2001-05-31 Seikagaku Corporation Method of treating surface tissue diseases
WO2001039795A2 (en) 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
ATE357506T1 (en) 2000-01-21 2007-04-15 Biomarin Pharm Inc FLAVOBACTERIUM HEPARINUM EXPRESSION SYSTEM
AU4351201A (en) 2000-03-08 2001-09-17 Massachusetts Inst Technology Heparinase iii and uses thereof
ATE426805T1 (en) 2000-09-12 2009-04-15 Massachusetts Inst Technology METHODS AND PRODUCTS ASSOCIATED WITH LOW MOLECULAR HEPARIN
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2441986A1 (en) 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
US20040214228A9 (en) * 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
CA2459040A1 (en) * 2001-09-14 2003-03-27 Mimeon, Inc. Methods of making glycolmolecules with enhanced activities and uses thereof
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
EP1518120A4 (en) * 2002-03-11 2008-08-13 Momenta Pharmaceuticals Inc Analysis of sulfated polysaccharides
WO2003090696A2 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
EP1575534B1 (en) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase and uses thereof
WO2004055491A2 (en) 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
EP1532241B1 (en) 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US20040147033A1 (en) * 2002-12-20 2004-07-29 Zachary Shriver Glycan markers for diagnosing and monitoring disease
JP4606712B2 (en) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
KR100846449B1 (en) * 2003-03-27 2008-07-16 삼성전자주식회사 Method for setting web camera mode of mobile composition device
EP1631237B1 (en) 2003-05-16 2016-11-30 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
WO2005026720A1 (en) * 2003-09-04 2005-03-24 Parivid Llc Methods and apparatus for characterizing polymeric mixtures
US7851223B2 (en) * 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
AU2005219413A1 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
CA2566731C (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093563A (en) * 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAUNG ET AL: "Active site of chondroitin AC lyase revealed by the structure of enzyme-oligosaccharide complexes and mutagenesis", BIOCHEMISTRY, vol. 40, no. 8, 2001, pages 2359 - 2372, XP002978618 *
HAUNG ET AL: "Crystal structure of chondroitinase B from Flavobacterium heparinum and its complex with a disaccharide product at 1.7 A resolution", J. MOL. BIOL., vol. 294, 1999, pages 1257 - 1269, XP004461802 *
POJASEK ET AL: "Biochemical characterization of the chondroitinase B active site", J. BIOL. CHEM., vol. 277, no. 34, August 2002 (2002-08-01), pages 31179 - 31186, XP002978617 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939292B2 (en) 2000-03-08 2011-05-10 Massachusetts Institute Of Technology Modified heparinase III and methods of sequencing therewith
US7687479B2 (en) 2000-09-12 2010-03-30 Massachusetts Institute Of Technology Methods and producing low molecular weight heparin
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US8018231B2 (en) 2002-05-20 2011-09-13 Massachussetts Institute Of Technology Method for sequence determination using NMR
US8529889B2 (en) 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US7842492B2 (en) 2007-01-05 2010-11-30 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US8846363B2 (en) 2007-01-05 2014-09-30 James R. Myette Compositions of and methods of using sulfatases from Flavobacterium heparinum

Also Published As

Publication number Publication date
EP1532241A4 (en) 2005-12-14
ATE481478T1 (en) 2010-10-15
CA2493509C (en) 2010-03-09
AU2003243396A1 (en) 2003-12-19
US7129335B2 (en) 2006-10-31
US6962699B2 (en) 2005-11-08
EP1532241B1 (en) 2010-09-15
EP1532241A2 (en) 2005-05-25
CA2493509A1 (en) 2003-12-11
US20070065424A1 (en) 2007-03-22
US20050227320A1 (en) 2005-10-13
US20040091472A1 (en) 2004-05-13
WO2003102160A2 (en) 2003-12-11
AU2003243396A8 (en) 2003-12-19
US7105334B2 (en) 2006-09-12
DE60334220D1 (en) 2010-10-28
US20050233419A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2003102160A3 (en) Rationally designed polysaccharide lyases derived from chondroitinase b
WO2001066772A3 (en) Heparinase iii and uses thereof
Pereira et al. Structure and anticoagulant activity of a sulfated galactan from the red alga, Gelidium crinale. Is there a specific structural requirement for the anticoagulant action?
WO2005087920A3 (en) Recombinant chondroitinase abc i and uses thereof
WO2007126727A8 (en) WATER SOLUBLE β-GLUCAN, GLUCOSAMINE, AND N-ACETYLGLUCOSAMINE COMPOSITIONS AND METHODS FOR MAKING THE SAME
ATE277157T1 (en) CLEANING PROCEDURE FOR STARCH REMOVAL
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
AU2001275651A1 (en) Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
MXPA02006145A (en) Method for isolation of rna from formalinfixed paraffinembedded tissue specimens.
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2001066553A3 (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
AU2002952681A0 (en) System and Method(s) of Mine Planning, Design and Processing
HK1044115A1 (en) Immunoadsorber for use in sepsis therapy
AU2235802A (en) Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation
AU2001265828A1 (en) Steeping process
PL375693A1 (en) Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups
WO2004002239A3 (en) Purified amylase inhibitor and novel process for obtaining the same
IL173850A0 (en) Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method
WO2005062739A3 (en) S-allylmercaptocysteine prodrugs and methods of treatment
DE60305169D1 (en) THERAPEUTIC PREPARATIONS CONTAINED MODIFIED POLYSACCHARIDES
FR2893504B1 (en) PROCESS FOR OBTAINING AN ACTIVE ACTIVE PRINCIPLE OF SKIN MECHANICAL RESISTANCE, ACTIVE INGREDIENT AND COMPOSITIONS
AU714164B2 (en) Modified pectin material
AU2002362020A1 (en) CRBs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHOD OF USE
WO2002058713A8 (en) Method for obtaining an isolated extract of the plant cyclamen europaeum l. and its use as a therapeutic agent
WO2002070712A3 (en) Chitin deacetylase and method for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003756399

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2493509

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2003756399

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP